Full-Time
Associate Director
Global Pricing Strategy & Analytics
Updated on 5/26/2026
Revolution Medicines
1,001-5,000 employees
Clinical-stage oncology company developing RAS inhibitors
No salary listed
Remote in USA
Remote
 Business & Strategy (1) |
|---|
- Bachelor’s degree required; advanced degree (MBA, MPH, PhD, PharmD, or equivalent) preferred.
- 6+ years of experience in pharmaceutical/biotech industry, with strong focus on pricing, market access, or commercial analytics.
- Support the development and execution of global pricing strategies for pipeline products across key markets.
- Establish pricing guidance, guardrails, and launch sequencing strategies to optimize global value.
- Evaluate pricing scenarios considering payer dynamics, competitive landscape, and regulatory constraints.
- Support early asset strategy by integrating pricing considerations into clinical and commercial planning.
- Design and deliver advanced pricing and access analytics, including price-volume trade-offs, corridor analyses, and international reference pricing (IRP) impact.
- Develop and maintain pricing models to inform decision-making at global and regional levels.
- Generate insights from real-world data, market research, and analog products to support pricing decisions.
- Monitor pricing performance and identify risks/opportunities post-launch.
- Drive pricing governance processes, including global price approvals and exception management.
- Ensure compliance with global pricing policies and external regulations.
- Partner with regional and country teams to support local price setting and negotiations.
- Collaborate closely with Market Access, HEOR, Commercial, Finance, and Legal teams.
- Align pricing strategies with value proposition, evidence generation, and reimbursement pathways.
- Provide strategic input into business development opportunities, including licensing and acquisitions.
- Develop global pricing infrastructure including systems, tools, and analytical platforms.
- Contribute to the development of pricing frameworks, dashboards, and best practices.
- Experience in global pricing strategy and launch pricing preferred.
- Experience with oncology or specialty therapeutics.
- Familiarity with international reference pricing (IRP), health technology assessment (HTA), and access pathways.
- Experience supporting pipeline assets and early commercialization strategy.
Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2014
Simplify's Take
What believers are saying
- RAS mutations drive about 90% of pancreatic cancers, expanding addressable patients.
- April 2026 Phase 3 data cut death risk about 60%, accelerating approval chances.
- The $2 billion financing funds multiple trials without immediate dilution pressure.
What critics are saying
- FDA review can still reject daraxonrasib after expanded access and positive interim data.
- Rash, mucositis, and gastrointestinal toxicity will limit dose intensity and real-world adoption.
- Heavy R&D losses and $1.7-1.8 billion 2026 expenses force repeated capital raises.
What makes Revolution Medicines unique
- Daraxonrasib is the first oral RAS(ON) inhibitor showing Phase 3 pancreatic survival benefit.
- Revolution’s platform targets active RAS, unlike older drugs limited to specific mutations.
- Zoldonrasib extends the franchise into KRAS G12D, a major unmet-need mutation.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Revolution Medicines who can refer or advise you
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -2%Ben Sasse's pancreatic cancer response is giving new hope to patients watching experimental treatments closely. When someone with stage 4 pancreatic cancer says their tumors shrank by more than 70%, people pay attention. That's exactly what happened when former U.S. Senator Ben Sasse shared details about his response to an experimental drug called daraxonrasib. According to recent reports, Sasse entered a clinical trial after being diagnosed with metastatic pancreatic cancer that had already spread to other organs, including his liver and lungs. Doctors initially gave him only months to live. Now, after several months on the drug, he says his tumor burden has dropped dramatically. That doesn't mean pancreatic cancer suddenly has a cure. Not even close. But stories like this matter because they show something many patients and families already believe deep down. Cancer research is moving fast. Faster than most people realize. And for people facing diagnoses with limited standard treatment options, experimental therapies often become more than a headline. They become a source of hope. What is daraxonrasib? Daraxonrasib is an experimental targeted therapy being developed by Revolution Medicines. The drug is designed to target KRAS mutations, genetic alterations that play a major role in many cancers, especially pancreatic cancer. KRAS mutations are notoriously difficult to treat. For years, researchers referred to them as "undruggable." That phrase has started disappearing lately. Daraxonrasib works by interfering with mutated KRAS proteins that help cancer cells grow and spread uncontrollably. Early clinical trial data suggest the drug may significantly extend survival in some pancreatic cancer patients who have already gone through chemotherapy. Some reports from recent Phase 3 trial data showed median survival reaching 13.2 months compared to 6.7 months with chemotherapy alone. That may not sound dramatic to someone outside the cancer world. But pancreatic cancer is one of the deadliest cancers known. Even modest gains matter. Doubling survival time gets attention in oncology circles. Why pancreatic cancer is so difficult. Pancreatic cancer often grows quietly. Symptoms tend to appear late. By the time many patients are diagnosed, the disease has already spread beyond the pancreas. That's one reason survival rates remain so low compared to many other cancers. Researchers continue exploring new approaches, including: * Targeted therapies * Immunotherapy * Personalized cancer vaccines * Metabolic therapies * Combination treatment strategies * KRAS inhibitors like daraxonrasib Recently, experimental pancreatic cancer vaccines targeting KRAS mutations have also shown encouraging early results in some patients. You can feel the momentum building. Not just in one lab or one company. Across multiple areas of research. The part many headlines leave out. Sasse has also been very open about the side effects. In interviews, he described severe skin reactions, bleeding, fatigue, and painful complications from the drug. He even referred to it as a "nasty drug." That's important context. Experimental therapies can produce remarkable responses in some patients. They can also come with serious risks, unknowns, and difficult tradeoffs. Clinical trials exist partly because researchers are still learning who responds best, how long responses last, and what side effects patients may face. Not hype. Not despair either. Just honest curiosity about where cancer treatment may be heading. Why patients are paying attention. For many families dealing with pancreatic cancer, the standard roadmap can feel painfully short. So when patients hear about therapies that target specific mutations, personalized vaccines, or unexpected tumor regression, they start asking questions. They begin researching clinical trials. They look into precision medicine. They wonder whether their tumor has a KRAS mutation. They ask about genomic testing. Honestly, that shift may be one of the biggest developments in modern cancer care. Patients are becoming more informed. More engaged. More willing to explore emerging options alongside conventional treatment. And physicians are increasingly using genetic profiling to guide treatment decisions instead of relying only on cancer location or stage. A reminder worth holding onto. No single story proves a treatment works for everyone. But individual cases still matter. They remind people that research is ongoing. That outcomes are not always predictable. That medicine keeps evolving. Five years ago, many people had never heard of KRAS-targeted therapies. Now some researchers believe this category of drugs could open an entirely new chapter in pancreatic cancer treatment. For patients facing difficult diagnoses, even the possibility of another option matters. And sometimes, that's enough to keep people searching, asking questions, and refusing to give up.
Revolution Medicines announced that its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial, nearly doubling survival time and reducing death risk by 60% compared to chemotherapy. Patients taking the daily pill typically survived 13.2 months versus 6.7 months with chemotherapy. The drug targets RAS mutations found in approximately 90% of pancreatic cancer cases. CEO Mark Goldsmith called the results "unprecedented", noting no drug has previously shown an overall survival benefit exceeding one year in Phase 3 pancreatic cancer trials. Revolution Medicines plans to seek FDA approval using a Commissioner's National Priority Voucher for expedited review. The approval would apply to second-line treatment for patients whose cancer progressed on other therapies. A separate Phase 3 trial for newly diagnosed patients is ongoing.
Sasse spotlight on potential pancreatic cancer cure. health April 11, 2026 health pancreatic cancer drug development RAS mutations Revolution Medicines' experimental drug daraxonrasib is showing promise as a potential breakthrough treatment for pancreatic cancer, garnering attention and driving up the company's stock. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, a drug that targets RAS mutations, which are present in about 90% of pancreatic cancer cases. The company anticipates releasing results from a Phase 3 trial soon, and it may become the first targeted treatment for this aggressive cancer. This development has significantly boosted RevMed's stock, increasing by nearly 185% over the past year, also making the company a prime acquisition target, according to reports. The drug gained recent attention when former Senator Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer, disclosed he is taking daraxonrasib. Sasse reported to The New York Times that his tumors have shrunk by 76% since starting the treatment. He did, however, note the drug's harsh side effects, including a rash that caused significant skin peeling. Despite these side effects, initial results are encouraging the medical community and patients. Why it matters. Pancreatic cancer is one of the deadliest forms of cancer, with only about 13% of patients surviving five years after diagnosis. This survival rate has remained relatively stagnant despite advancements in treating other cancers, making the unmet need for new therapies critically important. RBC Capital Markets analyst Leonid Timashev described RevMed's drug as potentially the biggest breakthrough in pancreatic cancer ever, highlighting the significance of a targeted treatment. Daraxonrasib aims to address the core mechanisms driving tumor growth in most pancreatic cancer cases, offering hope for improved outcomes. The broad targeting action of daraxonrasib on RAS mutations, while beneficial in attacking the cancer, also presents challenges. RAS proteins are widespread throughout the body, particularly in the skin, and the drug doesn't differentiate between mutated and normal RAS proteins. This leads to side effects such as rashes, as experienced by Senator Sasse. RevMed acknowledges these side effects but states that most rash cases have been low grade, and no patients have discontinued treatment due to them. The company describes reports of bleeding rashes as uncommon. What comes next. RevMed is proceeding with caution in its drug development, acknowledging the potential risks associated with daraxonrasib's broad RAS-targeting mechanism. CEO Mark Goldsmith noted the company started with a very low dose and gradually increased it, carefully monitoring patient tolerance. The company's scientists predicted that at 80 milligrams, tumors would start to shrink, a milestone they anxiously anticipated. The upcoming release of Phase 3 trial results will be crucial in determining the long-term efficacy and safety profile of daraxonrasib. Positive outcomes could lead to regulatory approval and make the drug available to a broader patient population. Continued monitoring for adverse effects and refinement of dosing strategies will also be essential to optimize treatment outcomes and improve patient quality of life. The drug's potential impact on the pharmaceutical landscape as a targeted therapy is significant. Faq. What is daraxonrasib and how does it work? What are the potential side effects of daraxonrasib? What stage of development is daraxonrasib in?
Sasse spotlights potential pancreatic cancer breakthrough. health April 10, 2026 health pancreatic cancer daraxonrasib Revolution Medicines Former Senator Ben Sasse's experience with Revolution Medicines' daraxonrasib has brought attention to a possible breakthrough in pancreatic cancer treatment, a disease with historically poor survival rates. What happened. Revolution Medicines (RevMed) is developing daraxonrasib, an experimental drug that may become the first targeted treatment for pancreatic cancer. The company anticipates releasing results from a Phase 3 trial soon. Former Senator Ben Sasse, diagnosed with Stage 4 pancreatic cancer, is currently taking daraxonrasib. Sasse reported that his tumors have shrunk by 76% since starting the treatment, although he also noted significant side effects, including a severe rash. Sasse's public disclosure of his treatment has drawn significant attention to RevMed and its drug. The potential of daraxonrasib has already boosted RevMed's stock by nearly 185% over the past year, making the company an attractive acquisition target. The drug broadly targets RAS mutations, found in nearly 90% of pancreatic cancer cases. These mutations drive tumor growth, making them a key target for cancer therapy. While Sasse's experience is anecdotal, it has fueled optimism surrounding the drug's potential efficacy. Why it matters. Pancreatic cancer is one of the deadliest major cancers, with only 13% of patients surviving five years after diagnosis. This grim statistic has remained largely unchanged despite advancements in treating other cancers. Currently, there is no targeted treatment specifically for pancreatic cancer. Daraxonrasib represents a significant potential advancement because it directly targets the RAS mutations that are central to the disease's progression. RBC Capital Markets analyst Leonid Timashev described the drug as potentially the biggest breakthrough in pancreatic cancer ever. The drug's mechanism of action, while promising, also contributes to its side effects. RAS proteins are present throughout the body, and daraxonrasib cannot differentiate between mutated and normal RAS proteins. This broad activity leads to side effects like the rash experienced by Sasse. Despite these side effects, RevMed reports that most rash cases have been low grade, with no patients discontinuing treatment as a direct result. However, severe cases, including those with bleeding, have been reported anecdotally by clinical trial investigators. What comes next. RevMed is nearing the release of its Phase 3 trial results, which will be crucial in determining the drug's efficacy and safety profile. The company's initial cautious approach to dosing reflects concerns about tolerability, as daraxonrasib's broad activity against RAS proteins could lead to severe side effects. CEO Mark Goldsmith explained the painstaking process of gradually escalating the dose while closely monitoring patient response. The company's scientists had predicted that tumor shrinkage would begin at 80 milligrams. If the Phase 3 trial results are positive, daraxonrasib could become the first targeted treatment for pancreatic cancer, potentially transforming the prognosis for patients. The drug's success could also make RevMed a prime acquisition target for larger pharmaceutical companies. However, longer-term data will be required to understand the extent of rash severity and other side effects, and to ascertain whether daraxonrasib has lasting impact on survival rates. Further studies and patient testimonials will be essential to fully measure the efficacy and tolerability of daraxonrasib. Related topics on gab.ae: ai Faq. What is daraxonrasib? What are the side effects of daraxonrasib? What impact has the drug had on the company stock?
Revolution Medicines shares have declined 8.8% in the month following its latest earnings report, underperforming the S&P 500. The biotech company reported a fourth-quarter 2025 loss of $1.86 per share, wider than the Zacks Consensus Estimate of a loss of $1.56. The company currently has no approved products or revenue. Research and development expenses rose 57% year over year to $294.9 million, driven by higher clinical study and manufacturing costs. General and administrative expenses increased more than 136% to $66.7 million. For 2026, Revolution Medicines expects operating expenses between $1.6 billion and $1.7 billion. Since the earnings release, analyst estimates have trended downward, with the consensus estimate shifting 7.21% lower. The stock maintains a Zacks Rank of Hold.